Trichomonas vaginalis

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

Volumn 2, Issue , 2014, Pages 3161-3164.e1

  Schwebke, Jane R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Candida infections; Metronidazole; Sexually transmitted disease (STD); Trichomonas; Vaginal pH; Vaginitis

Indexed keywords

EID: 84944578477     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4801-3.00282-4     Document Type: Chapter

References (79)

1. Honigberg B, King VM Structure of Trichomonas vaginalis Donne. J Parasitol 1964, 50:345-364.
2. Dyall SD, Johnson PJ Origins of hydrogenosomes and mitochondria: evolution and organelle biogenesis. Curr Opin Microbiol 2000, 3:404-411.
3. Burgess D, Knoblock KF Identification of Tritrichomonas foetus in sections of bovine placental tissue with monoclonal antibodies. J Parasitol 1989, 75:977-980.
4. Phillip A, Carter-Scott P, Rogers C An agar culture technique to quantitate Trichomonas vaginalis from women. J Infect Dis 1987, 155:304-308.
5. Arroyo R, Engbring J, Alderete J Molecular basis of host epithelial cell recognition by Trichomonas vaginalis. Mol Microbiol 1992, 6:853-862.
6. Niccolai L, Kopicko JJ, Kassie A, et al. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis 2000, 27:284-288.
7. Honigberg B, Burgess DE Trichomonads of importance in human medicine including Dientamoeba fragilis. Parasitic Protozoa 1994, Vol 9:1-109. Academic Press, New York.
8. Mason P, Patterson BA Proliferative response of human lymphocytes to secretory and cellular antigens of Trichomonas vaginalis. J Parasitol 1985, 71:265-268.
9. Cu-Uvin S, Ko H, Jamieson DJ, et al. HIV Epidemiology Research Study (HERS) Group. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002, 34:1406-1411.
10. Wølner-Hanssen P, Krieger JN, Stevens CE, et al. Clinical manifestations of vaginal trichomoniasis. JAMA 1989, 261:571-576.
11. Carlton JM, Hirt RP, Silva JC, et al. Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis. Science 2007, 315:207-212.
12. Sorvillo F, Kerndt P Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet 1998, 351:213-214.
13. Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin Infect Dis 2007, 45:1319-1326.
14. Weinstock H, Berman S, Cates W Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004, 36:6-10.
15. Cates W American Social Health Association Panel. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sex Transm Dis 1999, 26:S2-S7.
16. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993, 7:95-102.
17. Lossick J Epidemiology of urogenital trichomoniasis. Trichomonads Parasitic in Humans 1989, 311-341. Springer-Verlag, New York. B.M. Honigberg (Ed.).
18. Wilcox R Epidemiological aspects of human trichomoniasis. Br J Vener Dis 1960, 36:167-174.
19. Krieger JN, Verdon M, Siegel N, et al. Natural history of urogenital trichomoniasis in men. J Urol 1993, 149:1455-1458.
20. Joyner J, Douglas J, Ragsdale S, et al. Comparative prevalence of infection with Trichomonas vaginalis among men attending a sexually transmitted diseases clinic. Sex Transm Dis 2000, 27:236-240.
21. Schwebke JR, Hook EW High rates of Trichomonas vaginalis among men attending a sexually transmitted diseases clinic: implications for screening and urethritis management. J Infect Dis 2003, 188:465-468.
22. Seña AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis 2007, 44:13-22.
23. Danesh IS, Stephen JM, Gorbach J Neonatal Trichomonas vaginalis infection. J Emerg Med 1995, 13:51-54.
24. al-Salihi FL, Curran JP, Wang J Neonatal Trichomonas vaginalis: report of three cases and review of the literature. Pediatrics 1974, 53:196-200.
25. Jones JG, Yamaguchi T, Lambert B Trichomonas vaginalis infes-tations in sexually abused girls. Am J Dis Child 1985, 139:846-847.
26. Hesseltine H Experimental human vaginal trichomoniasis. J Infect Dis 1942, 71:127.
27. Rein MF, Muller M Trichomonas vaginalis and trichomoniasis. Sex Trans Dis 1990, 481-492.
28. Fouts AC, Kraus SJ Trichomonas vaginalis reevaluation of its clinical presentation and laboratory diagnosis. J Infect Dis 1980, 177:167-174.
29. Krieger JN Trichomoniasis in men: old issues and new data. Sex Transm Dis 1995, 22:83-96.
30. Schwebke J, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens-a randomized clinical trial. Clin Infect Dis 2011, 52:163-170.
31. Krieger JN, Tam MR, Stevens CE, et al. Diagnosis of trichomoniasis: comparison of conventional wet-mount examination with cytologic studies, cultures, and monoclonal antibody staining of direct specimens. JAMA 1988, 259:1223-1227.
32. Martin DH, Zozaya M, Lillis RA, et al. Unique vaginal microbiota that includes an unknown Mycoplasma-like organism is associated with Trichomonas vaginalis infection. J Infect Dis 2013, 207:1922-1931.
33. Draper D, Parker R, Patterson E, et al. Detection of Trichomonas vaginalis in pregnant women with the InPouch TV system. J Clin Microbiol 1993, 31:1016-1018.
34. Briselden AM, Hillier SL Evaluation of Affirm VP microbial identification test for Gardnerella vaginalis and Trichomonas vaginalis. J Clin Microbiol 1994, 32:148-152.
35. Kurth A, Whittington WLH, Golden MR, et al. Performance of a new, rapid assay for Trichomonas vaginalis. J Clin Microbiol 2004, 42:2940-2943.
36. Schwebke J, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective US clinical trial. J Clin Microbiol 2011, 49:4106-4111.
37. Nye MB, Schwebke JR, Body BA Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture and PCR for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol 2009, 200:188.e1-188.e7.
38. Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2006, 55(RR-11):49-56.
39. Roe F Safety of nitroimidazoles. Scand J Infect Dis Suppl 1985, 46:72-81.
40. Wood B, Monroe A Pharmacokinetics of tinidazole and metronidazole after single large oral doses. Br J Vener Dis 1975, 51:51-53.
41. Schwebke JR, Barrientes FJ Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother 2006, 50:4209-4210.
42. Land KM, Delgadillo-Correa MG, Tachezy J, et al. Targeted gene replacement of a ferredoxin gene in Trichomonas vaginalis does not lead to metronidazole resistance. Mol Microbiol 2003, 51:115-122.
43. Crowell A, Sanders-Lewis KA, Secor WE In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother 2003, 47:1407-1409.
44. Sobel J, Nyirjesy P, Brown W Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001, 33:1341-1346.
45. Sobel J, Nagappan V, Nyirjesy P Metronidazole-resistant vaginal trichomoniasis-an emerging problem. N Engl J Med 1999, 341:292-293.
46. Nyirjesy P, Gilbert J, Mulcahy LJ Resistant trichomoniasis: successful treatment with combination therapy. Sex Transm Dis 2011, 38:962-963.
47. Muzny C, Barnes A, Mena L Symptomatic Trichomonas vaginalis infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid. Sex Health 2012, 9:389-391.
48. Pearlman M, Yashar C, Ernst S, et al. An incremental dosing protocol for women with severe vaginal trichomoniasis and adverse reactions to metronidazole. Am J Obstet Gynecol 1996, 174:934-936.
49. Cotch MF, Pastorek JG, Nugent RP, et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. Sex Transm Dis 1997, 24:361-362.
50. Minkoff H, Grunebaum AN, Schwarz RH, et al. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol 1984, 150:965-972.
51. Klebanoff M, Carey J, Hauth J, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001, 345:487-493.
52. Kigozi G, Brahmbhatt H, Wabwire-Mangen F, et al. Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 2003, 189:1398-1400.
53. Soper DE, Bump RC, Hurt WG Bacterial vaginosis and trichomoniasis vaginitis are risk factors for cuff cellulitis after abdominal hysterectomy. Am J Obstet Gynecol 1990, 163:1016-1023.
54. Leroy V, De Clercq A, Ladner J, et al. Should screening of genital infections be part of antenatal care in areas of high HIV prevalence? A prospective cohort study from Kigali, Rwanda, 1992-1993. Genitourin Med 1995, 71:207-211.
55. McClelland R, Sangare L, Hassan W, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007, 195:698-702.
56. Hobbs M, Kazembe P, Reed A, et al. Trichomonas vaginalis as a cause of urethritis in Malawian men. Sex Transm Dis 1999, 26:381-387.
57. Price M, Zimba D, Hoffman IF, et al. Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. Sex Transm Dis 2003, 30:516-522.
58. Dyall SD, Johnson PJ Origins of hydrogenosomes and mitochondria: evolution and organelle biogenesis. Curr Opin Microbiol 2000, 3:404-411.
59. Cu-Uvin S, Ko H, Jamieson DJ, et al. HIV Epidemiology Research Study (HERS) Group. Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis 2002, 34:1406-1411.
60. Wølner-Hanssen P, Krieger JN, Stevens CE, et al. Clinical manifestations of vaginal trichomoniasis. JAMA 1989, 261:571-576.
61. Carlton JM, Hirt RP, Silva JC, et al. Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis. Science 2007, 315:207-212.
62. Sutton M, Sternberg M, Koumans EH, et al. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. Clin Infect Dis 2007, 45:1319-1326.
63. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993, 7:95-102.
64. Krieger JN, Verdon M, Siegel N, et al. Natural history of urogenital trichomoniasis in men. J Urol 1993, 149:1455-1458.
65. Schwebke JR, Hook EW High rates of Trichomonas vaginalis among men attending a sexually transmitted diseases clinic: implications for screening and urethritis management. J Infect Dis 2003, 188:465-468.
66. Seña AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis 2007, 44:13-22.
67. Rein MF, Muller M Trichomonas vaginalis and trichomoniasis. Sex Trans Dis 1990, 481-492.
68. Schwebke J, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens-a randomized clinical trial. Clin Infect Dis 2011, 52:163-170.
69. Martin DH, Zozaya M, Lillis RA, et al. Unique vaginal microbiota that includes an unknown Mycoplasma-like organism is associated with Trichomonas vaginalis infection. J Infect Dis 2013, 207:1922-1931.
70. Kurth A, Whittington WLH, Golden MR, et al. Performance of a new, rapid assay for Trichomonas vaginalis. J Clin Microbiol 2004, 42:2940-2943.
71. Schwebke J, Hobbs MM, Taylor SN, et al. Molecular testing for Trichomonas vaginalis in women: results from a prospective US clinical trial. J Clin Microbiol 2011, 49:4106-4111.
72. Nye MB, Schwebke JR, Body BA Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture and PCR for diagnosis of trichomoniasis in men and women. Am J Obstet Gynecol 2009, 200:188.e1-188.e7.
73. Centers for Disease Control and Prevention Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2006, 55(RR-11):49-56.
74. Crowell A, Sanders-Lewis KA, Secor WE In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother 2003, 47:1407-1409.
75. Sobel J, Nyirjesy P, Brown W Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001, 33:1341-1346.
76. Sobel J, Nagappan V, Nyirjesy P Metronidazole-resistant vaginal trichomoniasis-an emerging problem. N Engl J Med 1999, 341:292-293.
77. Klebanoff M, Carey J, Hauth J, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med 2001, 345:487-493.
78. McClelland R, Sangare L, Hassan W, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007, 195:698-702.
79. Price M, Zimba D, Hoffman IF, et al. Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. Sex Transm Dis 2003, 30:516-522.